Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function

Human Molecular Genetics

Volumn 14, Issue 24, 2005, Pages 3885-3897

  Wang, Cheng ^a,b   Ko, Han Seok ^c   Thomas, Bobby ^c   Tsang, Fai ^b   Chew, Katherine C M ^a,b   Tay, Shiam Peng ^a   Ho, Michelle W L ^a   Lim, Tit Meng ^b   Soong, Tuck Wah ^b   Pletnikova, Olga ^c   Troncoso, Juan ^c   Dawson, Valina L ^c   Dawson, Ted M ^c   Lim, Kah Leong ^a,b  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; IRON; NEUROTOXIN; NITRIC OXIDE; OXIDOPAMINE; PARAQUAT; PARKIN; PROTEASOME; ROTENONE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; RISK FACTOR; SOLUBILITY; STRESS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BRAIN; CELLS, CULTURED; DOPAMINE; HUMANS; HYDROGEN PEROXIDE; MALE; MICE; MICE, INBRED C57BL; MUTATION; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PARAQUAT; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; REFERENCE VALUES; ROTENONE; SOLUBILITY; STRESS; UBIQUITIN-PROTEIN LIGASES;

ANIMALIA;

EID: 29644448325     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddi413     Document Type: Article

References (44)

1. Dawson, T.M. and Dawson, V.L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science, 302, 819-822.
2. Lim, K.L., Dawson, V.L. and Dawson, T.M. (2003) The cast of molecular characters in Parkinson's disease: Felons, conspirators, and suspects. Ann. NY Acad. Sci., 991, 80-92.
3. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 55-84.
4. Imai, Y. and Takahashi, R. (2004) How do parkin mutations result in neurodegeneration? Curr. Opin. Neurobiol., 14, 384-389.
5. Mata, I.F., Lockhart, P.J. and Farrer, M.J. (2004) Parkin genetics: One model for Parkinson's disease. Hum. Mol. Genet., 13, R127-R133.
6. Foroud, T., Uniacke, S.K., Liu, L., Pankratz, N., Rudolph, A., Halter, C., Shults, C., Marder, K., Conneally, P.M. and Nichols, W.C. (2003) Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology, 60, 796-801.
7. Kann, M., Jacobs, H., Mohrmann, K., Schumacher, K., Hedrich, K., Garrels, J., Wiegers, K., Schwinger, E., Pramstaller, P.P., Breakefield, X.O. et al. (2002) Role of parkin mutations in 111 community-based patients with early-onset Parkinsonism. Ann. Neurol., 51, 621-625.
8. West, A.B., Maraganore, D., Crook, J., Lesnick, T., Lockhart, P.J., Wilkes, K.M., Kapatos, G., Hardy, J.A. and Farrer, M.J. (2002) Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet., 11, 2787-2792.
9. Feany, M.B. and Pallanck, L.J. (2003) Parkin: A multipurpose neuroprotective agent? Neuron, 38, 13-16.
10. Higashi, Y., Asanuma, M,, Miyazaki, I., Hattori, N., Mizuno, Y. and Ogawa, N. (2004) Parkin attenuates manganese-induced dopaminergic cell death. J. Neurochem., 19, 1490-1497.
11. Petrucelli, L., O'Farrell, C., Lockhart, P.J., Baptista, M., Kehoe, K., Vink, L., Choi, P., Wolozin, B., Farrer, M., Hardy, J. et al. (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron, 36, 1007-1019.
12. Tsai, Y.C., Fishman, P.S., Thakor, N.V. and Oyler, G.A. (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem., 278, 22044-22055.
13. Yang, Y., Nishimura, I., Imai, Y., Takahashi, R. and Lu, B. (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron, 37, 911-924.
14. Ko, H.S., von Coelln, R., Sriram, S.R., Kim, S.W., Chung, K.K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E.L. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci., 25, 7968-7978.
15. Staropoli, J.F., McDermott, C., Martinat, C., Schulman, B., Demireva, E. and Abeliovich, A. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron, 37, 735-749.
16. Darios, F., Corti, O., Lucking, C.B., Hampe, C., Muriel, M.P., Abbas, N., Gu, W.J., Hirsch, E.C., Rooney, T., Ruberg, M. et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet., 12, 517-526.
17. Jiang, H., Ren, Y., Zhao, J. and Feng, J. (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet., 13, 1745-1754.
18. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L and Dawson, T.M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA, 97, 13354-13359.
19. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144-1150.
20. Kalia, S.K., Lee, S., Smith, P.D., Liu, L., Crocker, S.J., Thorarinsdottir, T.E., Glover, J.R., Fon, E.A., Park, D.S. and Lozano, A.M. (2004) BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron, 44, 931-945.
21. Yamada, M., Mizuno, Y. and Mochizuki, H. (2005) Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease. Hum. Gene Ther., 16, 262-270.
22. Lo Bianco, C., Schneider, B.L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T. and Aebischer, P. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 101, 17510-17515.
23. Pawlyk, A.C., Giasson, B.I., Sampathu, D.M., Perez, F.A., Lim, K.L., Dawson, V.L., Dawson, T.M., Palmiter, R.D., Trojanowski, J.Q. and Lee, V.M. (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem., 278, 48120-48128.
24. Wang, C., Tan, J.M., Ho, M.W., Zaiden, N., Wong, S.H., Chew, C.L., Eng, P.W., Lim, T.M., Dawson, T.M. and Lim, K.L. (2005) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem., 93, 422-431.
25. Sriram, S.R., Li, X., Ko, H.S., Chung, K.K., Wong, E., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet., 14, 2571-2586.
26. Winklhofer, K.F., Henn, I.H., Kay-Jackson, P.C., Heller, U. and Tatzelt, J. (2003) Inactivation of parkin by oxidative stress and C-terminal truncations: A protective role of molecular chaperones. J. Biol. Chem., 278, 47199-47208.
27. Chung, K.K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J.C., Marsh, L., Dawson, V.L. and Dawson, T.M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 304, 1328-1331.
28. Lotharius, J. and Brundin, P. (2002) Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci., 3, 932-942.
29. Tsirigotis, M., Zhang, M., Chiu, R.K., Wouters, B.G. and Gray, D.A. (2001) Sensitivity of mammalian cells expressing mutant ubiquitin to protein-damaging agents. J. Biol. Chem., 276, 46073-46078.
30. Lim, K.L., Dawson, V.L. and Dawson, T.M. (2005) Parkin-mediated lysine 63-linked polyubiquitination - a link to Lewy body formation? Neurobiol. Aging, Epub ahead of print October 5, 2005.
31. Di Monte, D.A., Lavasani, M. and Manning-Bog, A.B. (2002) Environmental factors in Parkinson's disease. Neurotoxicology, 23, 487-502.
32. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M. and Wolozin, B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci., 20, 6048-6054.
33. Paxinou, E., Chen, Q., Weisse, M., Giasson, B.I., Norris, E.H., Rueter, S.M., Trojanowski, J.Q., Lee, V.M. and Ischiropoulos, H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci., 21, 8053-8061.
34. Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R. and Greenamyre, J.T. (2002) An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci., 22, 7006-7015.
35. Imai, Y., Soda, M. and Takahashi, R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol, Chem., 275, 35661-35664.
36. McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P. and Olanow, C.W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol., 179, 38-46.
37. Doss-Pepe, E.W., Chen, L. and Madura, K. (2005) Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem., 280, 16619-16624,
38. Lim, K.L., Chew, K.C., Tan, J.M., Wang, C., Chung, K.K., Zhang, Y., Tanaka, Y., Smith, W., Engelender, S., Ross, C.A. et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation. J. Neurosci., 25, 2002-2009.
39. Jenner, P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol., 53 (Suppl. 3), S26-S36; discussion S36-S28.
40. Tonks, N.K. (2005) Redox redux: Revisiting PTPs and the control of cell signaling. Cell, 121, 667-670.
41. Cookson, M.R., Lockhart, P.J., McLendon, C., O'Farrell, C., Schlossmacher, M. and Farrer, M.J. (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet., 12, 2957-2965.
42. Gu, W.J., Corti, O., Araujo, F., Hampe, C., Jacquier, S., Lucking, C.B., Abbas, N., Duyckaerts, C., Rooney, T., Pradier, L. et al. (2003) The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis., 14, 357-364.
43. Sriram, S.R., Li, X., Ko, H.S., Chung, K.K., Wong, E., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of Parkin. Hum. Mol. Genet., 14, 2571-2586.
44. Yao, D., Gu, Z., Nakamura, T., Shi, Z.Q., Ma, Y., Gaston, B., Palmer, L.A., Rockenstein, E.M., Zhang, Z., Masliah, E. et al. (2004) Nitrosative stipss linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad, Sci. USA, 101, 10810-10814.